ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 389,73
-0,79%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NYSE
  6. AbbVie Inc (ABBV)

  7. AbbVie Inc (ABBV) Actualités

ABBV

AbbVie (ABBV)

AbbVie Inc
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:ABBV
DateHeureSourceTitreSymboleSociété
26/04/202413h47IH Market NewsU.S. Futures Climb in Pre-Market Trading Amid Tech Gains and Upcoming Inflation DataNYSE:ABBVAbbVie Inc
26/04/202413h35PR Newswire (US)AbbVie Reports First-Quarter 2024 Financial ResultsNYSE:ABBVAbbVie Inc
25/04/202414h00PR Newswire (US)New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis StudyNYSE:ABBVAbbVie Inc
23/04/202414h00PR Newswire (US)Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest BrandsNYSE:ABBVAbbVie Inc
18/04/202414h31PR Newswire (US)Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell ArteritisNYSE:ABBVAbbVie Inc
12/04/202413h30PR Newswire (US)AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of MigraineNYSE:ABBVAbbVie Inc
09/04/202414h00PR Newswire (US)SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to AcneNYSE:ABBVAbbVie Inc
04/04/202414h00PR Newswire (US)AbbVie to Host First-Quarter 2024 Earnings Conference CallNYSE:ABBVAbbVie Inc
03/04/202414h30PR Newswire (US)Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®NYSE:ABBVAbbVie Inc
01/04/202413h50GlobeNewswire Inc.NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-YearNYSE:ABBVAbbVie Inc
26/03/202412h20IH Market NewsSuper Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest NewsNYSE:ABBVAbbVie Inc
25/03/202416h00PR Newswire (US)Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in AestheticsNYSE:ABBVAbbVie Inc
25/03/202413h31PR Newswire (US)AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesNYSE:ABBVAbbVie Inc
22/03/202420h02PR Newswire (US)U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer PatientsNYSE:ABBVAbbVie Inc
21/03/202413h00PR Newswire (US)ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024NYSE:ABBVAbbVie Inc
07/03/202414h00PR Newswire (US)AbbVie to Present at the Barclays 26th Annual Global Healthcare ConferenceNYSE:ABBVAbbVie Inc
06/03/202414h03PR Newswire (US)AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics PortfoliosNYSE:ABBVAbbVie Inc
05/03/202423h30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:ABBVAbbVie Inc
05/03/202418h09PR Newswire (Canada)Dragonfly a reçu un paiement d'étape à la suite de la prise de dose du premier patient à l'essai clinique de phase 1 d'AbbVie évaluant le DF4101/ABBV-303NYSE:ABBVAbbVie Inc
05/03/202414h00PR Newswire (US)JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA ApprovalNYSE:ABBVAbbVie Inc
05/03/202413h00PR Newswire (US)Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303NYSE:ABBVAbbVie Inc
02/03/202401h53Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNYSE:ABBVAbbVie Inc
28/02/202406h05PR Newswire (US)AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic InflammationNYSE:ABBVAbbVie Inc
27/02/202414h00GlobeNewswire Inc.Healis Therapeutics' asset CKDB-501A shares Phase III topline results for glabellar injections from CKD Bio in South KoreaNYSE:ABBVAbbVie Inc
27/02/202414h00PR Newswire (US)AbbVie to Present at the TD Cowen 44th Annual Health Care ConferenceNYSE:ABBVAbbVie Inc
27/02/202413h45PR Newswire (US)U.S. Food and Drug Administration (FDA) Grants Priority Review of Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma (FL)NYSE:ABBVAbbVie Inc
26/02/202423h08Edgar (US Regulatory)Form 8-K - Current reportNYSE:ABBVAbbVie Inc
26/02/202412h12Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NYSE:ABBVAbbVie Inc
22/02/202414h05PR Newswire (US)AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and ImmunologyNYSE:ABBVAbbVie Inc
21/02/202414h00PR Newswire (US)BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women EntrepreneursNYSE:ABBVAbbVie Inc
 Showing the most relevant articles for your search:NYSE:ABBV

Dernières Valeurs Consultées

EU
MC
Lvmh Moet Hennessy Louis...
NASDAQ
AMZN
Amazon.com
NASDAQ
GOOGL
Alphabet
EU
ML
Michelin
NASDAQ
MSFT
Microsoft
NASDAQ
AAPL
Apple
NYSE
NKE
Nike
NYSE
JPM
JP Morgan Chase
EU
RI
Pernod Ricard
EU
VIV
Vivendi
EU
BEL20
Bel 20
NYSE
MCD
McDonalds
EU
ACA
Credit Agricole
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés